Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR Study

Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR Study

10.1080/10428194.2017.1376743

Saved in:
Bibliographic Details
Main Authors: Hartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, Ruben Niesvizky, Wee Joo Chng, Douglas Joshua, Katja Weisel, Andrew Spencer, Robert Orlowski, Shibao Feng, Karim Iskander, Meletios A. Dimopoulos
Other Authors: MEDICINE
Format: Others
Published: Taylor & Francis 2018
Online Access:http://scholarbank.nus.edu.sg/handle/10635/143070
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore

Internet

http://scholarbank.nus.edu.sg/handle/10635/143070

Similar Items